- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00171054
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
June 2, 2011 updated by: Novartis
A Randomized, Double-blind, Parallel Group, Active-controlled, 38-week Study to Evaluate the Efficacy of Valsartan Versus Amlodipine on the Arterial Properties of Postmenopausal Women With Mild to Moderate Hypertension
The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic, hydrochlorothiazide.
In particular, the effect of treatment on the stiffness of the blood vessels will be studied.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
125
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Basel, Switzerland
- Novartis Pharmaceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Postmenopausal women
- Mild to moderate hypertension
- Statin therapy or LDL≤ 4.1 mmol/L
Exclusion Criteria:
- Severe hypertension
- LDL > 4.1 mmol/L if not taking anti-hyperlipidemic medication
- Certain hormonal therapy
- History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
- Liver, kidney, or pancreas disease
- Diabetes
- Raynaud's disease or any other significant peripheral vascular disease
- Allergy to certain medications used to treat high blood pressure
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Valsartan 320 mg
|
Patients received 160 mg valsartan for 4 weeks.
Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
|
Experimental: Amlodipine 10 mg
|
At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
Patients received 5 mg amlodipine for four weeks.
Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)
Time Frame: Baseline and Week 38
|
PWV was determined from transcutaneous Doppler flow recordings and the foot-to-foot method triggered by the simultaneous ECG.
Two simultaneous Doppler flow tracings were taken at the left common carotid and the right femoral artery in the groin with a linear array probe.
The time delay (t) was measured between R wave of the ECG and the base of the flow waves recorded at these points, and averaged over 10 beats.
The distance (D) traveled by the pulse wave was measured over body surface as the distance from the suprasternal notch to the carotid artery.
PWV was calculated as PWV=D/t.
|
Baseline and Week 38
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12
Time Frame: Baseline and Week 12
|
Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter.
The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist.
All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated.
All measurements were made in a quiet room with a patient in the supine position.
The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).
|
Baseline and Week 12
|
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)
Time Frame: Week 38
|
Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter.
The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist.
All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated.
All measurements were made in a quiet room with a patient in the supine position.
The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).
|
Week 38
|
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12
Time Frame: Baseline and Week 12
|
Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia.
FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.
|
Baseline and Week 12
|
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)
Time Frame: Baseline and Week 38
|
Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia.
FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.
|
Baseline and Week 38
|
Changes in Mean Left Carotid Distensibility at Week 12
Time Frame: Baseline and Week 12
|
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe.
Absolute diameter and diameter changes over the cardiac cycles will be recorded.
Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
|
Baseline and Week 12
|
Changes in Mean Left Carotid Distensibility at Week 38
Time Frame: Baseline and Week 38
|
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe.
Absolute diameter and diameter changes over the cardiac cycles will be recorded.
Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
|
Baseline and Week 38
|
Changes in Mean Right Carotid Distensibility at Week 12
Time Frame: Baseline and Week 12
|
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe.
Absolute diameter and diameter changes over the cardiac cycles will be recorded.
Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
|
Baseline and Week 12
|
Changes in Mean Right Carotid Distensibility at Week 38
Time Frame: Baseline and Week 38
|
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe.
Absolute diameter and diameter changes over the cardiac cycles will be recorded.
Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
|
Baseline and Week 38
|
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12
Time Frame: Baseline and Week 12
|
The calculation of spontaneous baroflex sensitivity was obtained by the sequence method.
Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased.
The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).
|
Baseline and Week 12
|
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38
Time Frame: Baseline and Week 38
|
The calculation of spontaneous baroflex sensitivity was obtained by the sequence method.
Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased.
The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).
|
Baseline and Week 38
|
Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38
Time Frame: Baseline and Week 38
|
Baseline and Week 38
|
|
Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38
Time Frame: Baseline, Week 12 and Week 38
|
Central Blood Pressure was measured via applanation tonometry recordings of the common carotid artery and from brachial oscillometric recordings.
The Simultaneously obtained carotid artery pressure and standard brachial artery blood pressure are computed to obtain the central systolic pressure.
|
Baseline, Week 12 and Week 38
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2003
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
September 10, 2005
First Submitted That Met QC Criteria
September 10, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Estimate)
June 6, 2011
Last Update Submitted That Met QC Criteria
June 2, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Valsartan
- Hydrochlorothiazide
Other Study ID Numbers
- CVAL489A2418
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Valsartan 320 mg
-
NovartisThe TIMI Study GroupCompletedMyocardial Ischemia | Post Acute Coronary SyndromeGermany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
-
GE HealthcareCompletedCoronary Artery DiseaseFrance
-
Palobiofarma SLFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauTerminated
-
PfizerCompleted
-
Prolong PharmaceuticalsCompletedAnemia, Sickle CellColombia, Panama, Dominican Republic, Honduras
-
Novartis PharmaceuticalsCompletedEssential HypertensionJapan
-
Novartis PharmaceuticalsCompletedHypertensionSweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
-
Novartis PharmaceuticalsCompletedDiabetes Mellitus, Type 2Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more